Tag: Chymodiactin

Anaphylaxis, a severe allergic reaction, occurred in up to 1% of patients treated with chymopapain, contributing to a complex debate about its safety. This article explores the full story of why was chymopapain discontinued despite its effectiveness for many.

An estimated 80% of people will experience back pain at some point, with some cases resulting from herniated discs. For a time, the drug chymopapain was used for a procedure called chemonucleolysis to address this issue, but its use was ultimately discontinued due to significant risks.